170115-98-7

Basic information

• Product Name: (R,R)-(-)-PSEUDOEPHEDRINE GLYCINAMIDE
• Synonyms: (R,R)-(-)-PSEUDOEPHEDRINE GLYCINAMIDE;[2-[[(1R,2R)-1-hydroxy-1-phenylpropan-2-yl]-methylamino]-2-oxoethyl]azanium
• CAS NO: 170115-98-7
• Molecular Formula: C₁₂H₁₈N₂O₂
• Molecular Weight: 222.28
• Product Categories: pharmacetical
• Mol File: 170115-98-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 397.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.140±0.06 g/cm3(Predicted)
• PKA: 13.71±0.20(Predicted)
• CAS DataBase Reference: (R,R)-(-)-PSEUDOEPHEDRINE GLYCINAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (R,R)-(-)-PSEUDOEPHEDRINE GLYCINAMIDE(170115-98-7)
• EPA Substance Registry System: (R,R)-(-)-PSEUDOEPHEDRINE GLYCINAMIDE(170115-98-7)

Safety Data

• Hazardous Substances Data: 170115-98-7(Hazardous Substances Data)

Usage

Description

(R,R)-(-)-Pseudoephedrine Glycinamide is an organic compound with a unique molecular structure, characterized by its chiral centers and amino acid-like properties. It serves as a crucial building block in the development of various pharmaceutical compounds due to its versatile reactivity and structural features.

Uses

Used in Pharmaceutical Industry:
(R,R)-(-)-Pseudoephedrine Glycinamide is used as a building block for the synthesis of macrocyclic trypanosomal cysteine protease inhibitors. These inhibitors are essential in the development of treatments for trypanosomal diseases, such as African sleeping sickness, by targeting and inhibiting the activity of specific proteases in the parasite.
Additionally, (R,R)-(-)-Pseudoephedrine Glycinamide is used as a building block in the synthesis of α-amino acids. These amino acids are vital components in the development of various pharmaceutical compounds, including those with potential applications in the treatment of neurological disorders, cancer, and other diseases. The unique structural properties of (R,R)-(-)-Pseudoephedrine Glycinamide make it a valuable asset in the design and synthesis of novel therapeutic agents.

Upstream product

• 4530-20-5 BOC-glycine 
• 321-97-1 (1R,2R)-pseudoephedrine 
• 616-34-2 methoxycarbonylmethylamine 
• 170115-96-5 2-amino-N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methylacetamide 
• 5680-79-5 glycine ethyl ester hydrochloride 
• 3282-30-2 pivaloyl chloride 

Downstream Products

• 173913-77-4 <-2S>-N-(2-hydroxy-1-methyl-2-phenylethyl)-N-methyl 2-amino-3-(2-(5-benzenesulfonyloxy)pyridyl)propionamide 
• 176754-77-1 Carbonic acid 5-{(S)-2-amino-2-[((1R,2R)-2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-carbamoyl]-ethyl}-4-(tert-butoxycarbonylamino-methyl)-2-methyl-pyridin-3-yl ester tert-butyl ester 
• 213881-33-5 ((R,R)-2S)-N-(2-hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-amino-3-[2-(8-benzenesulfonyloxy)quinolinyl]propionamide 
• 225938-47-6 <1R(S),2R>-N-(2-hydroxy-1-methyl-2-phenethyl)-2-amino-N-methyl-4-pentenamide 

Relevant articles and documents

NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF

The present invention relates to oligomer compounds, including dimers and trimers, formed by a disulfide, sulfinyl thio, olefin or hydrocarbon bond, or a hydrazone exchange bond between two or more monomers. Methods of making the monomers and the oligomers is also disclosed. Use of the compounds for inhibiting the activity of target RNA molecules, particularly those having a secondary structure that include a stem or stem-loop formation. Dimer compounds capable of inhibiting the activity of an HIV-1 RNA frameshifting stem-loop and a (CUG)n expanded repeat stem- loop are disclosed, as are methods of treating diseases associated with these target RNA molecules.

Enantioselective Synthesis of Non-Natural Aromatic α-Amino Acids

We present two complementary methods for the stereoselective synthesis of non-natural α-amino acids with aromatic or heteroaromatic side chains. One approach is based on the chemical transformation of methionine, whereas the other applies the stereoselective Myers alkylation of glycine. The resulting product types differ in the linker length between glycine and the aromatic substituent. Since methionine and pseudoephedrine are available in both absolute configurations, R- or S-configured enantiopure amino acids with either C2 or C3 linkers can be obtained on gram scales. In each case the key step of the synthesis is hydroboration of the unsaturated building blocks 9 and 17, followed by palladium-catalyzed Suzuki cross-coupling with aryl halides. Attention must in certain cases be paid to the stereochemical integrity when basic Suzuki conditions are applied. Our initial difficulties are reported as well as the final "racemization-proof" procedures. The protecting groups chosen for the α-amino acids should be compatible with solid-phase peptide synthesis. This was confirmed by the successful synthesis of a series of tripeptides.

The Synthesis of Two Furan-Based Analogues of the α′,β ′-Epoxy Ketone Proteasome Inhibitor Eponemycin

Myers's methodology for enantioselective amino acid synthesis was employed to prepare the N-Boc didehydroleucine amide derivative 15 and to effect its conversion into the acylfuran intermediate 17. Coupling of 19 (R = H) with N-(isooctanoyl)serine provided the furan-based analogue 4 of eponemycin (de = 96 %), a peptide epoxide with potent cytotoxic and anti-angiogenesis properties. In an identical fashion the corresponding unsaturated analogue 5 of eponemycin was prepared (de = 48%). Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003.